Welcome to the e-CCO Library Archive!

search
                             
search by: 
Filter:
P017. Prostaglandin E2 regulates intestinal inflammation and modifies in vivo and in vitro extracellular matrix regulation
P017. Th2 cytokines and cAMP mediated induction of SOCS3 expression in inactive ulcerative colitis
P017. The miRNA-29 family regulates NOD2-dependent IL-23 expression in human DCs and limits intestinal pathology in a mouse model of mucosal inflammation
Authors:

O. Brain1, B. Owens1, M.-Y. Sun2, S. Schonefeldt3, P. Allan1, T. Pichulik2, E. Khatamzas2, D. Jewell1, A. Liston3, A. Simmons1,2, 1University of Oxford, TGU, Nuffield Dept of Medicine, Oxford, United Kingdom, 2Weatherall Institute of Molecular Medicine, MRC Human Immunology Unit, Oxford, United Kingdom, 3KU Leuven, VIB Autoimmune Genetics Laboratory, Leuven, Belgium

P017

Long-term stimulation with cytokines acquires irreversible accumulation of NF-κB signaling in colonic epithelial cells

Authors:

S. Hibiya*1, K. Tsuchiya2, K. Fukushima1, R. Hayashi3, N. Horita1, S. Oshima1, R. Okamoto2, T. Nakamura2, M. Watanabe1

1Tokyo Medical and Dental University, Gastroenterology and Hepatology, Tokyo, Japan, 2Tokyo Medical and Dental University, Advanced Therapeutics for Gastrointestinal Diseases, Tokyo, Japan, 3Hiroshima University Hospital, Gastroenterology and Metabolism, Hiroshima, Japan

P018.

The anti-inflammatory cytokine IL-10 is an important mediator of the action of the TLR-9 agonist DIMS0150

Authors:

C. Admyre, P. von Stein, T. Knittel, O. von Stein, A. Zargari, InDex Pharmaceuticals AB, R&D Department, Stockholm, Sweden

P018. Linking risk conferring mutations in NCF4 to functional consequences in Crohn's disease
P018. Successful treatment of acute TNBS-mediated colitis in mice by selective glucocorticoid receptor agonists (SEGRAs) – anti-inflammatory effects and improved safety profile
P018. The role of human colonic ion transporters in diarrhea-associated diseases
Authors:

É. Pallagi-Kunstár1, K. Farkas1, Z. Rakonczay Jr.1, F. Nagy1, Z. Szepes1, V. Venglovecz2, Z. Rázga3, J. Maléth1, T. Wittmann1, T. Molnár1, P. Hegyi1, 1University of Szeged, First Department of Medicine, Szeged, Hungary, 2University of Szeged, Department of Pharmacology and Pharmacotherapy, Szeged, Hungary, 3University of Szeged, Department of Pathology, Szeged, Hungary

P018

Role of CCL20-CCR6 axis and MMP9 in the mucosal inflammation and fibrosis in Inflammatory Bowel Disease

Authors:

O. Inczefi*1, 2, T. Molnár1, A. Bálint1, R. Dainese3, M. Lévêque2, V. Bacquié2, C. Salvador-Cartier2, A. Rosztóczy1, R. Róka1, T. Piche3, V. Theodorou2, L. Ferrier2

1University of Szeged, 1st Department of Medicine, Szeged, Hungary, 2INRA TOXALIM , Neurogastrogastroenteorology and Nutrition Unit, Toulouse, France, 3CHU de Nice, Department of Gastroenterology, Nice, France

P019.

T cell specific loss of PTPN2 results in aggravated colitis and pronounced intestinal dysbiosis as observed in Crohn's disease patients

Authors:

M. Spalinger1, C. Chassard2, S. Kasper1, L. Biedermann1, S. Vavricka3, I. Frey-Wagner1, K. Atrott1, C. Lacroix2, M. Fried1,4, G. Rogler1,4, M. Scharl1,4, 1University Hospital Zurich, Gastroenterology & Hepatology, Zurich, Switzerland, 2ETH Zurich, Institute of Food, Nutrition and Health, Zurich, Switzerland, 3Hospital Triemli, Gastroenterology & Hepatology, Zurich, Switzerland, 4Zurich Institute for Human Physiology, University Zürich, Zürich, Switzerland

P019. Expression of intestinal alpha-defensins in paediatric inflammatory bowel disease
P019. Internalization of the vedolizumab/α4β7 complex and kinetics of restoring functional activity
P019. The role of human neutrophil elastase and its inhibitor elafin in ulcerative colitis
Authors:

K. Kok1, R. Curciarello1, P. Biancheri1, L. Langmead2, T. MacDonald1, 1Barts and The London School of Medicine and Dentistry, Centre for Immunology and Infectious Disease, London, United Kingdom, 2Royal London Hospital, Gastroenterology, London, United Kingdom

P019

Determinism of enteric glial reactivity in Inflammatory Bowel Disease

Authors:

M. Freyssinet*, T. Clairembault, S. Coquenlorge, J. Jaulin, E. Coron, S. Bruley des Varannes, M. Neunlist, M. Rolli-Derkinderen, A. Bourreille

U913, INSERM, Neuro-Gastroenterologie, Nantes, France

P020.

Silencing of prolyl hydroxylase 1 in intestinal microvascular endothelial cells prevents inflammation-induced endothelial dysfunction and dampens murine colitis

Authors:

S. Van Welden1, D. Laukens1, L. Devisscher1, H. Devlies1, K. Olievier1, C. Correale2, S. D'Alessio2, S. Danese2, M. De Vos1, P. Hindryckx1, 1Ghent University, Department of Gastroenterology, Gent, Belgium, 2Humanitas Research Hospital, IBD Unit – Gastroenterology, Milano, Italy

P020. Interleukin-17A but not interleukin-17E is profibrotic in the gut of patients with Crohn's disease
P020. Selective glucocorticoid receptor agonists (SEGRAs) in intestinal disease – promising effects for inflammation and intestinal tissue repair in vitro
P020. The Th17 cell population in the peripheral blood in patients with Crohn's disease
Authors:

K. Radwan1, P. Radwan2, A. Surdacka3, C. Lozowski2, B. Skrzydlo-Radomanska2, J. Rolinski3, 1Central Clinical Hospital of Internal Affairs, Warsaw, Internal Medicine and Gastroenterology, Warsaw, Poland, 2Medical University of Lublin, Gastroenterology, Lublin, Poland, 3Medical University of Lublin, Clinical Immunology, Lublin, Poland

P020

Quantification of the concentration of antibodies against Infliximab in human serum using a pure antibody as calibrator

Authors:

B. Hernández-Breijo1, M. Chaparro*2, I.D. Román1, J. Monserrat3, D. Cano-Martínez1, P. Sanmartín-Salinas1, I. Guerra4, M. Iborra5, J.L. Cabriada6, L. Bujanda7, C. Taxonera8, V. García-Sánchez9, I. Marín-Jiménez10, M. Barreiro de-Acosta11, I. Vera12, M.D. Martín-Arranz13, A. López-San Román14, L. Sempere15, F. Gomollón16, M.D. Hinojosa17, J.P. Gisbert2, L. Guijarro1

1Universidad de Alcalá and CIBERehd, Systems Biology, Alcalá de Henares, Spain, 2Hospital Universitario de La Princesa, IIS-IP and CIBERehd, Gastroenterology Unit, Madrid, Spain, 3Universidad de Alcalá, Medicine and Medical Specialties, Alcalá de Henares, Spain, 4Hospital Universitario de Fuenlabrada, Gastroenterology Unit, Madrid, Spain, 5Hospital Universitario La Fe and CIBERehd, Gastroenterology Unit, Valencia, Spain, 6Hospital Galdakao, Gastroenterology Unit, Vizcaya, Spain, 7Hospital de Donostia, Instituto Biodonostia, UPV/EHU and CIBEREHD, Gastroenterology Unit, Guipuzcoa, Spain, 8Hospital Clínico Universitario San Carlos and IdISSC, Gastroenterology Unit, Madrid, Spain, 9Hospital Universitario Reina Sofía, Gastroenterology Unit, Córdoba, Spain, 10Hospital General Universitario Gregorio Marañón, Gastroenterology Unit, Madrid, Spain, 11Complejo Hospitalario Universitario de Santiago, Gastroenterology Unit, Santiago de Compostela, Spain, 12Hospital Universitario Puerta de Hierro , Gastroenterology Unit, Madrid, Spain, 13Hospital Universitario La Paz , Gastroenterology Unit, Madrid, Spain, 14Hospital Universitario Ramón y Cajal, Gastroenterology Unit, Madrid, Spain, 15Hospital General Universitario de Alicante, Gastroenterology Unit, Alicante, Spain, 16Hospital Clínico Universitario Lozano Blesa and CIBERehd, Gastroenterology Unit, Zaragoza, Spain, 17Hospital de Manises, Gastroenterology Unit, Valencia, Spain

P021.

Roxithromycin inhibits nuclear factor kappaB signaling and endoplasmic reticulum stress in intestinal epithelial cells, and ameliorates experimental colitis

Authors:

S.-J. Koh1, J.W. Kim1, J.P. Im2, J.S. Kim2, 1Seoul National University Boramae Hospital, Internal Medicine, Seoul, Korea, Republic of, 2Seoul National University College of Medicine, Department of Internal Medicine and Liver Research Institute, Seoul, Korea, Republic of